Non-NK1 Receptor Antagonists Effective Against Chemotherapy-Induced Nausea and Vomiting
the Cancer Therapy Advisor take:
Chemotherapy-induced nausea and vomiting (CINV) can have a serious impact on a patient’s quality of life. Without an anti-emetic drug, more than 90% of patients who receive highly emetic chemotherapy agents will experience nausea and/or vomiting.
The authors of a recent review published in the journal Supportive Care in Cancer sought to examine the effects of a combination of adjunctive non-neurokinin 1 receptor antagonist (NK1RA) drugs with 5- hydroxytryptamine 3 (5-HT3) antagonists on adult cancer patients who were administered moderate- or highly emetogenic chemotherapy.
In this study, CINV was classified according to the timing of its occurrence, with acute CINV occurring and resolving within the first 24 hours after chemotherapy, and delayed, after the first 24 hours. Thirteen previous studies, which included 1,669 patients, were reviewed, and a higher level of protection against CINV was observed with the adjunctive medications; however, delayed control of CINV did not improve.
Although symptoms of nausea and vomiting are less severe in the delayed period, they can last longer and therefore result in dehydration and nutritional impairment. The overall complete control of CINV was increased by the adjunctive administration of NK1Ras, but further research is needed into combining these medications into new regimens with 5-HT3 and NK1 antagonists.
Combination of adjunctive NK1RA drugs with 5-HT3 antagonists in moderate- or highly emetogenic chemotherapy examined.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer